Drug interactions;Arzneimittelinteraktionen

Internist

Volumn 51, Issue 3, 2010, Pages 359-370

  Hafner, V ^a   Grun B ^a   Markert, C ^a   Czock, D ^a   Mikus, G ^a   Haefeli, W E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cytochrome; Drug interaction; Drug transporter; Pharmacodynamic; Pharmacokinetic

Indexed keywords

ABC TRANSPORTER; ACETYLCYSTEINE; AMIODARONE; ATORVASTATIN; BENZODIAZEPINE; CARBAMAZEPINE; CARBIDOPA; CLARITHROMYCIN; CYTOCHROME P450; DICLOFENAC; DIOXIN; ETORICOXIB; FLUMAZENIL; HALOPERIDOL; HEPARIN; ITRACONAZOLE; LEVODOPA; MORPHINE; NALOXONE; NAPROXEN; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROTAMINE; RIFABUTIN; RIFAMPICIN; SPIRONOLACTONE; UNINDEXED DRUG; VERAPAMIL;

DNA POLYMORPHISM; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; NEPHROTOXICITY; OTOTOXICITY; REVIEW;

DRUG INTERACTIONS; DRUG TOXICITY; HUMANS;

EID: 77951498610     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-009-2553-1     Document Type: Review

References (21)

1. Bailey DG, Spence JD, Munoz C et al. (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268-269
2. Baxter K (2008) Stockleys drug interactions. Pharmaceutical Press, London
3. Bertsche T, Pfaff J, Schiller P et al. (2010) Prevention of adverse drug reactions in intensive care patients by a personal intervention based on an electronic clinical decision support system. Intensive Care Med (in press)
4. Cancelli I, Beltrame M, Gigli GL et al. (2009) Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 30: 87-92
5. Cuisset T, Frere C, Quilici J et al. (2009) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (proton pump inhibitors and clopidogrel association) prospective randomized study. J Am Coll Cardiol 54: 1149-1153
6. Haefeli WE (2007) Drug-drug interactions with levodopa modulating treatment responses in Parkinsons disease. J Neurol 254 (Suppl 4): IV/29-IV/36
7. Hafner V, Jäger M, Matthée AK et al. (2010) Effect of simultaneous induction and inhibition of CYP3A by St Johns wort and ritonavir on CYP3A activity. Clin Pharmacol Ther [Epub ahead of print]
8. Ho PM, Maddox TM, Wang L et al. (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301: 937-944
9. Houston MC (1991) Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 90: S42-S47
10. Jost WH, Brück C (2002) Drug interactions in the treatment of Parkinsons disease. J Neurol 249: III24-III29
11. Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158: 693-705
12. Khalique SC, Cheng-Lai A (2009) Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 17: 198-200
13. Knoll B, Haefeli WE, Ladewig D et al. (1997) Early recurrence of withdrawal symptoms under phenytoin and chronic alcohol use. Pharmacopsychiatry 30: 72-73
14. Li XQ, Andersson TB, Ahlstrom M et al. (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32: 821-827
15. Martin-Facklam M, Rieger K, Riedel K-D et al. (2004) Undeclared exposure to St. Johns wort in hospitalized patients. Br J Clin Pharmacol 58: 437-441
16. ODonoghue ML, Braunwald E, Antman EM et al. (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374: 989-997
17. Okudaira T, Kotegawa T, Imai H et al. (2007) Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 47: 871-876
18. ORourke M, Xiong-Jing (2000) Sildenafil/ nitrate interaction. Circulation 99: 168-177
19. Rieger K, Scholer A, Arnet I et al. (2004) High prevalence of unknown co-medication in hospitalised patients. Eur J Clin Pharmacol 60: 363-368
20. Rivkin A (2007) Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 64: 1840-1843
21. Zhou ZW, Zhou SF (2009) Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol 5: 579-605